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C-reactive protein (CRP) 1 is the prototypical acute phase protein; serum levels 
of CRP  increase by as  much as  2,000-fold  during the first 24-48  h  after the 
onset of certain types of inflammation (1, 2). Although CRP was discovered over 
fifty years ago (3), subsequent studies have yet to uncover a unique function for 
CRP. It is believed that CRP resembles immunoglobulins because, when bound 
to certain ligands, it can promote reactions of precipitation (3,  4), complement 
fixation (5), and phagocytosis (6). Therefore, it has been reasonable to hypothe- 
size a unique function for CRP involving any or all of these phenomena. 
Recently (4),  chromatin  was described as being a  unique ligand for CRP;  it 
was demonstrated that binding of CRP  to  the nucleosome core particles,  the 
basic structure present in chromatin, occurred with an affinity of at least 2,400- 
times  the  affinity of CRP  binding  to  any  other  previously  described  ligand. 
Chromatin is a  term  used  to  describe  nuclear  DNA  complexed  to its natural 
proteins, most of which are histones. Individually, DNA and histones are highly 
water-soluble substances because of the respective polyanionic and polycationic 
charges. However, chromatin itself is an insoluble, sticky material as a  result of 
charge neutralization when the histones are electrostatically bound to DNA. 
In  view  of the  wide  range  of inflammatory conditions  in  which  insoluble 
chromatin  might be  released  from damaged cells and in  which CRP  levels in 
serum are elevated, we sought methods to verify in vitro our previous hypothesis 
(4) about the in vivo function of CRP, namely, that it mediates the removal of 
chromatin from the body after cell death.  In the present study, we performed 
experiments using the hemolytic activity of serum against sensitized sheep eryth- 
rocytes  and  chromatin  containing [~H]DNA  as  an  indicator  of very complex 
events in serum brought on by CRP-chromatin complexes. We found an associ- 
ation  between  the  degree  of chromatin  solubilized  by  serum  and  the  CRP 
concentration. Additionally, we found that some systemic lupus erythematosus 
(SLE) patients may have a  depressed mechanism to solubilize chromatin, which 
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may  contribute  to  the  induction  of  either  anti-DNA  antibody  formation  or 
pathogenic immune complexes found in many of these patients. 
Materials and  Methods 
Reagents.  Fresh human serum was prepared from clotted whole blood obtained from 
healthy  volunteers  and  stored  at  -20°C  until  use.  Serum  minus  C3  was  purchased 
commercially (Cappel Laboratories, Cochranville, PA). Serum genetically deficient in C2 
was provided by Dr. Michael Frank, National Institute of Allergy and Infectious Diseases 
(NIAID), and  purified  C2  was purchased  from Cordis  Laboratories,  Inc., Miami,  FL. 
Serum that had  been passed through  a  column  of Bio-Rex-70 (Bio-Rad  Laboratories, 
Richmond, CA) and was lacking C 1  q, and purified C 1  q prepared as described (26), were 
gifts from Dr. Andrea  Tenner,  NIAID. Rabbit antiserum to human  histone  H2B was 
provided by Dr. Michael Bustin, NCI, NIH. A WiDr cell line derived from human colon 
carcinoma specimens was provided by Mr. Robert Cunningham and Dr. Philip Noguchi, 
CDB/FDA. [SH]thymidine (sp act, 60 Ci/mmol) was from New England Nuclear, Boston, 
MA.  Brij  35  and N-a-p-tosyl-L-lysine chloromethyl  ketone  (TLCK) were  from  Sigma 
Chemical Co., St. Louis, MO. 
Preparation of Human  CRP from  Rheumatoid Arthritis Plasma.  Citrated  plasma was 
obtained by plasmapheresis from a rheumatoid arthritis patient hospitalized at the Clinical 
Center, NIH, Bethesda, MD.  Heparin (5,000  U) was added to 500 ml plasma, followed 
by 50 ml of a buffer containing 1.5  M NaCI, 0.5 M Tris, pH 7.4, and 0.1  M CaCI~. The 
heparinized plasma was then passed through a  1.5  ×  12 cm column containing phospho- 
rylcholine (PC)-Sepharose (7), and the PC-Sepharose was washed overnight with 900 ml 
of a  buffer  consisting  of 0.15  M  NaCI,  0.05  M  Tris,  pH  7.4,  and  0.01  M  CaCI2 
(Tris/saline/Ca2+), together with 1,000 U heparin. Additional washes were with 50 ml of 
the same Tris/saline/Ca  P+ buffer containing 0.3%  Brij  35, and with 50 ml Tris/saline/ 
Ca  P+ buffer containing NaCI to a final concentration of 2 M. Finally, the PC-Sepharose 
was washed with 50 ml of the Tris/saline/Ca  2+ buffer and the CRP was eluted with 0.1 
M PC in the same buffer. Those fractions having an A~80 >1.0 were pooled and dialyzed 
exhaustively against  0.15  M  NaCI, 0.05  M  Tris,  0.01  M  EDTA,  pH  7.4,  followed by 
dialysis against the Tris/saline/Ca P+ buffer. After the  readdition of Ca  P+ to the eluted 
protein sample, a precipitate formed in the dialysis bag. The precipitated material was 
found to be 90% serum amyloid P component, as determined by sodium dodecyl sulfate- 
polyacrylamide gel  electrophoresis  (SDS-PAGE)  (8),  amino  acid  analysis,  and  amino- 
terminal sequence analysis of the first 20 amino acids, all of whose results were in complete 
agreement with the properties previously described (9). CRP was found exclusively in the 
soluble fraction. The purity of the CRP was verified by SDS-PAGE (8). 
Assays for Serum Complement Consumption by CRP-Chromatin Complexes.  Chromatin 
from rabbit liver was prepared by the method of Rizzo and Bustin (10).  The microcom- 
plement  fixation  technique  as  described  by Champion  et  al.  (11)  was  modified after 
optimizing conditions by incubating 246 ~g chromatin with from 140 to  1 ~g]m[ CRP 
and 50 ~1 human serum in a  total volume of 1 ml. The buffer used was 0.15  M NaC1, 
0.05 M Tris, pH 7.4, 0.1  mM CaCi2, and 0.12 mM MgCi~. After the above mixture was 
incubated for 1 h at 37°C, 0.5 ml sensitized sheep red blood cells (3.7 ×  108 cells/ml) was 
added and the mixtures incubated at 37°C  for 20-30 rain. After the allotted time, the 
mixtures were centrifuged and the optical density of each supernatant was determined by 
spectrophotometry at 520 nm (sheep red cells [Cappel Laboratories] were sensitized by 
treating the cells in 2 ml buffer at 37°C for 30 min with 10 #1 rabbit anti-sheep red blood 
cell serum [Cappel Laboratories]). 
Chromatin Solubilization Assays.  Chromatin containing [SH]DNA was prepared as fol- 
lows: Rabbit lung fibroblasts or human WiDr cells from colon carcinoma specimens were 
grown  to  30-40%  confluency  in  twelve  150-cm  P tissue  culture  flasks (Corning  Glass 
Works, Corning, NY) in basal Eagle's medium (for the rabbit lung fibroblasts) or Eagle's 
minimum essential medium (for the WiDr cells),  each supplemented with  10% fetal calf 
serum and,  initially,  1 #Ci/ml of [3H]thymidine. After 24 h, the medium was replaced 1346  C-REACTIVE  PROTEIN  MEDIATES  CHROMATIN SOLUBILIZATION 
with medium containing 10% fetal calf serum but no [3H]thymidine. When the cells were 
finally confluent, they were washed twice in medium and, in  15 ml of hypotonic buffer 
containing  15 mM NaCI, 5 mM Tris, pH 7.4,  1 mM TLCK, and  I  mM CaCI2, the cells 
were  swollen  by  standing  at  4°C  for  30  min.  Nuclei  containing  the  [3H]DNA  were 
prepared by lysing the swollen cells with a  type B Dounce homogenizer in buffer, and 
washing the resulting nuclei with buffer containing 1% Triton X- 100. Nuclei were washed 
by centrifuging a  suspension  of the  nuclei  at  6,000  rpm  for  2  min,  withdrawing  the 
supernatant from the nuclear pellet, and gently resuspending the pellet in fresh buffer 
containing no TLCK or Triton X-100. Chromatin was prepared from the nuclei by the 
method described by Rizzo and Bustin (10). An average specific activity of ~1.5 ~Ci/mg 
DNA was obtained after several preparations.  The [SH]nuclei and [3H]chromatin were 
prepared on the same day that the experiments were conducted. 
[~H]Chromatin at concentrations of 2-5  mg per  10  ml in basal Eagle's medium was 
evenly suspended by gently homogenizing with a type B Dounce homogenizer. To several 
polypropylene tubes (12 ×  75 mm) containing 100 ~1 CRP of varying concentrations was 
added 200 ~1 [SH]chromatin suspension,  200 ~1 human serum, and 500 ~1 basal Eagle's 
medium.  The  tubes  were  then  collectively placed  into  a  Dubnoff metabolic shaking 
incubator at 37 °C for allotted times; the reaction was stopped by removing the contents 
of each tube and centrifuging for 5  min at  15,000  rpm in an Eppendorf microfuge at 
25°C.  The  supernatant  was  then  filtered  on  a  0.22-~m-pore  membrane  (Millipore/ 
Continental  Water  Systems, Bedford,  MA).  The quantity of solubilized  [~H]DNA was 
determined by placing 100 ~1 of the filtrate into  10 ml Aquasol (New England Nuclear) 
and  determining  the  radioactivity  using  an  LS  7800  scintillation  counter  (Beckman 
Instruments, Inc., Fullerton, CA). 
Studies on  CRP in SLE Plasma.  Patients  with  SLE  were  seen  in  the  outpatient  or 
inpatient  services of the  Arthritis  and  Rheumatism  Branch,  NIADDK at  the  Clinical 
Center of NIH.  All  patients  satisfied preliminary ARA  criteria  for SLE.  Plasma from 
these patients was citrated and stored at -70°C until use. 
The quantity of CRP  in  the plasma of SEE patients was determined by an enzyme- 
linked immunosorbent assay (ELISA) developed using purified CRP and affinity-purified 
goat anti-CRP, following the method of Voller et al. (12). The sensitivity of the assay was 
0.2 ng/ml. 
CRP was removed from SLE plasma using either the PC-Sepharose method outlined 
above for the removal of CRP from rheumatoid arthritis plasma or by antibody affinity 
chromatography.  For  the  antibody  affinity  chromatography  method,  affinity-purified 
sheep  anti-CRP  Ig  was  immobilized  to  Sepharose  using  activated  Sepharose  CH-4B 
(Pharmacia Fine Chemicals,  Piscataway, NJ).  Before adding the anti-CRP Sepharose to 
the  SLE plasma, the  resin  was  washed  in  two  column  volumes of 4  M  MgClz.  After 
reequilibration of the resin in 0.15 M NaCI, 0.05 M Tris, pH 7.4, we added 2 ml resin to 
50 ml heparinized SLE plasma and rotated the mixture overnight at 4°C. The resin was 
washed first with Tris/saline (100 ml), then with Tris/saline/0.3%  Brij 35 (50 ml), then 
with  Tris/saline  containing  2  M  NaC1 (50  ml),  and,  finally,  with  4  M  MgCI~.  Those 
fractions having an A~s0 >0.1  (full scale) were pooled, dialyzed against water, and dried 
for evaluation by SDS-PAGE. 
Results 
Complement Consumption  by CRP-Chromatin  Complexes.  Complement was pre- 
treated  with  chromatin  and  increasing  concentrations  of CRP at  37°C.  It was 
then assayed in a  hemolytic assay. With  increasing amounts of CRP and,  there- 
fore,  increasing  chromatin-CRP  complexes,  there  was  increasing  depletion  of 
complement  (Fig.  1).  Fig.  1  further  illustrates  that  chromatin  alone  does  not 
deplete the hemolytic complement of serum within  the incubation  time used (1 
h); nor does CRP alone, i.e., without chromatin (data not shown).  Preincubation 
of the serum for 30 min at 56 °C abolished the hemolytic activity. Results parallel ROBEY, JONES,  AND  STEINBERG  1347 
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FIC;UI~E  l.  Ability of CRP-chromatin complexes to deplete complement. Complement was 
pretreated with chromatin and varying concentrations of CRP, and then used in a hemolytic 
assay.  Curve shows  the  lysis of sensitized sheep  red cells by  pretreated  complement.  Plot 
represents the percent lysis as a function of CRP concentration used in the pretreatment. 
to  those  in  Fig.  1  were obtained  with  rabbit  CRP  and  rabbit  serum except, 
instead of 50 ~1 human serum, 200 #1 of rabbit serum (Cappei Laboratories) and 
a  2 h  preincubation period were required. It should be noted that the highest 
concentrations used in all of our experiments closely correspond to the concen- 
tration of CRP found in serum during the acute phase of inflammation (2). 
Solubilization of Chromatin by Complement Is Mediated by CRP.  Recently (13), 
Volanakis demonstrated that insoluble complexes of pneumococcal C-polysac- 
charide could be solubilized by complement (13).  In an effort to see if CRP- 
chromatin complexes could be  solubilized by complement, we prepared  [~H] 
chromatin by  growing cells  in  medium supplemented with  [3H]thymidine to 
specifically radiolabel the DNA. We were thus able to easily measure the solubility 
of DNA in a complex solution containing serum, media, and varying quantities 
of CRP  by quantifying the amount of radioactivity in supernatants after high 
speed centrifugation. 
The amount of [~H]DNA solubilized by complement was directly proportional 
to  the  concentration of CRP  present  (Figs.  2  and  3).  Fig.  2  represents  the 
complement-induced solubilization of isolated chromatin, whereas Fig. 3 shows 
the solubilization by complement of DNA from chromatin still in isolated nuclei. 
In Fig. 2, the chromatin was first mechanically homogenized for even suspension; 
this may have denatured the chromatin to some extent, resulting in more soluble 
DNA  at  low  CRP  concentrations  compared  with  that  in  the  isolated  nuclei 
experiment (Fig. 3). 
Nevertheless, these experiments clearly indicate that solubilization  of chro- 
matin  by  serum is  directly dependent on  the amount  of CRP  present.  It  is 
strongly suggested that complement is the solubilizing mechanism, because serum 
minus C3 did not solubilize chromatin even at high concentrations of CRP (Fig. 
3).  Additionally, complement is further implicated because heat-inactivated se- 
rum (56°C, 30 rain) did not solubilize the chromatin at high levels of CRP (Fig. 
2). 
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FIGURE 2.  Complement-induced  solubilization of chromatin as a function of CRP concentra- 
tion. With increasing CRP there was increasing amounts of ~H-labeled DNA released from 
chromatin. Heat inactivation to prevent complement activity prevented [SH]DNA release (0). 
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FIGURE 3.  Complement-induced solubilization of chromatin in isolated nuclei as a function 
of CRP concentration. With increasing CRP, increasing amounts of [3H]DNA were released. 
(A) Amount of DNA released by C3-deficient serum. 
sensitized  sheep red blood cells caused the solubilization  of chromatin  at high 
CRP  concentrations  (100-200  #g/ml).  However,  the  amount  of  chromatin 
solubilized in 1 h at 37 °C was only 20% of that obtained using normal serum or 
C2-deficient serum to which purified C2 had been added. These results indicate 
that  the  classical  complement  pathway  is  the  primary  pathway  involved  in 
solubilizing chromatin, although the alternative pathway is also involved. 
There  was no solubilization  of chromatin  via CRP using  serum  minus  Clq 
(prepared  by  Bio-Rex-70  chromatography  [26])  even  after  purified  Clq  was 
added back. However, after purified C 1  q was added back, the serum's hemolytic 
activity against sensitized sheep red blood cells was restored to ~60-70% of that ROBEY, JONES, AND  STEINBERG  1349 
obtained using whole serum (data not shown). These results suggest that passing 
the  serum  through  Bio  Rex-70  removed  some  factor(s),  in  addition to  Clq, 
which may be required for CRP to activate complement. 
When  1  mM  TLCK, a  protease  inhibitor,  was  included in  the  incubation 
medium, the amount of solubilized DNA at high concentrations of CRP  was 
-20% of that in the absence of inhibitor. This suggests that proteolysis is a major 
process in the solubilization of chromatin. 
A time course study (Fig. 4) indicated that most of the solubilization process is 
complete after 1 h and suggests that the solubilization mechanism is very complex 
and not a simple first-order reaction. However, serum constituted only 20% of 
the volume of the reaction mixture for these experiments. If we double or triple 
the percent of serum, we double and triple the rates of solubilization and the 
percent solubilized (data not shown). For example, using 100 #g/ml chromatin, 
100 #g/ml CRP, and 60% serum, there was 100% solubilization of the [~H]DNA 
after 1 h  at 37°C.  Under the same conditions, but with no added CRP, there 
was only 17% solubilization of the [aH]DNA after 1 h. 
Virtually all of the DNA solubilized was insoluble in 5% trichloroacetic acid. 
However, after treatment of the solubilized DNA with  1%  DNase I  for 1 h  at 
37°C,  virtually all  of the  DNA  was  soluble  in  5%  trichloroacetic acid.  This 
indicates that  the  [3H]thymidine radiolabel  was  in  the  DNA  instead of some 
other component. 
We were unable to determine the sizes of the solubilized DNA because of the 
slow degradation in serum.  However, after  1 h  incubation at 37°C, all of the 
solubilized DNA eluted in the void volume of a  TSK-300 column (molecular 
weight cutoff, ~300,000) in high performance liquid chromatography. After 18 
h  at  37°C,  only 22%  of the total radioactivity eluted (data not shown).  This 
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FIGURE  4.  Complement-induced  solubilization  of  chromatin  as  a  function  of  time.  The 
concentration  of chromatin used for each experiment was ~200 ~g/ml. High  (200 ~g/m[) and 
low (600 ng/ml) concentrations of CRP were studied. Incubations were at 37°C for the 
indicated times followed  by evaluation  of the cpm in the soluble fractions. ]350  C-REACTIVE  PROTEIN  MEDIATES  CHROMATIN  SOLUBILIZATION 
indicates that there are slow-acting nucleases in serum that are hydrolyzing the 
DNA and which complicate the characterization of the initial solubilized product. 
All of the studies described above using chromatin and nuclei from rabbit lung 
fibroblasts were repeated using preparations from a WiDr cell line obtained from 
a patient with carcinoma of the colon. Rabbit antiserum to human H2B precipi- 
tated 43%  of the total radioactivity in the solution containing solubilized DNA 
(data  not  shown),  whereas  normal  rabbit  serum  precipitated  no  detectable 
radioactivity. This indicates that H2B, a  core histone, is still bound to much of 
the DNA after solubilization. 
The sensitivity of these assays depended on several factors, such as the specific 
activity and  yield of the  chromatin  preparation.  For  unknown  reasons,  some 
chromatin would decompose, as determined by the amount of radioactivity in 
supernatants during the preparation process, but proper treatment of the nuclei 
with TLCK during preparation controlled the degradation. However, it is critical 
that residual TLCK be removed from the washed nuclei; otherwise, as mentioned 
above, the sensitivity of the assay is not as great. Provided there was no detectable 
decomposition of the chromatin during the purification process,  the sensitivity 
of these preparations was within about +30% of those in Figs. 2 and 3. 
Evaluation  of CRP in  SLE plasma.  It  is  well-known  that  patients with SLE 
have anti-DNA antibodies in their blood. We studied CRP levels in SLE plasma 
to see if a defect in the normal CRP-mediated solubilization of chromatin might 
be detectable in SLE plasma and thus present a possible reason for these patients 
having anti-DNA antibodies. Table  I  gives the values of CRP found in plasma 
obtained from eight SLE patients. We also evaluated seven normal samples and 
found the lowest amount of CRP in our small group of normals to be  190 ng/ 
ml. Patients 7 and 8 had extremely low levels of CRP in their plasma. It is highly 
likely that these amounts are overestimated, representing the background in our 
assay. We do not have a human sample known to have no CRP, and thus cannot 
definitively establish background data. 
For many of the SLE samples, PC-Sepharose  did not completely remove the 
TABLE  I 
Concentrations of CRP Levels in Plasma from SLE Patients as 
Determined by ELISA 
Patient  CRP 
ng/ml 
1  14,900 
2  2,300 
3  2,002 
4  661 
5  270 
6  116 
7  36 
8  21 
Lowest  value previously  reported in the literature was 68 ng/ml (2). Values 
from seven normal blood samples  were determined for these experiments: 
= 639 --- 477 ng/ml; max, 1,380 ng/ml; min, 190 ng/ml; median, 562 
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FIGURZ 5.  SDS-PAGE (8) of material from SLE plasma eluted from anti-CRP Sepharose. (1) 
Molecular weight standards; (A) nonreduced sample eluted  from anti-CRP Sepharose;  (B) 
reduced  (with  dithiothreitol) sample eluted  from  anti-CRP Sepharose.  50  ml  heparinized 
plasma from SLE patient No. 3 (Table I) was passed first through PC-Sepharose, then three 
times through a  column of sheep anti-mouse albumin Sepharose to remove crossreacting 
immunoglobulin.  The plasma was then treated with sheep anti-CRP Sepharose as described in 
Materials and  Methods.  The sample was  eluted with 4  M  MgCI2 before desalting and gel 
electrophoresis. The stacking gel was  7.5% bis-acrylamide; the separating gel was  13% bis- 
acrylamide. 
CRP shown  by ELISA  to be present  in  the plasma.  This  is in  contrast  to our 
findings with rheumatoid arthritis plasma, where PC°Sepharose did remove most 
of the CRP (unpublished data).  Therefore,  we constructed an anti-CRP Sepha- 
rose resin to remove CRP from one sample (No. 3 in Table I) and evaluated the 
CRP on polyacrylamide gels. 
Anti°CRP Sepharose was able to extract CRP from SLE plasma that had been 
previously passed through  the PC-Sepharose (Fig.  5A).  Also, when the sample 
used  in  lane  A  was  chemically  reduced  with  dithiothreitoi,  additional  bands 
appeared, corresponding to heavy and light chains, respectively, of immunoglob- 
ulin.  This result indicates that the one SLE sample tested contained antibodies 
against the CRP. It is possible that these antibodies blocked the binding of CRP 
to PC.  In conclusion,  two SLE patients had unusually low levels of CRP and a 
third patient had detectable antibodies reactive with her CRP. 
Discussion 
In previous work (4), it was shown that CRP bound strongly and specifically 
to chromatin  and chromatin  fragments and it was suggested that an important 
function of CRP might be to mediate the removal of chromatin from damaged 
tissue. In the present paper, we support this hypothesis with data clearly showing 
that the solubilization of chromatin by complement is mediated by CRP. 
The  significance  of this  is  twofold:  First,  it  indicates  that  the  body has  an 
efficient mechanism  with which to deal with nuclear components released from 
damaged tissue. Because chromatin  is the densest, most insoluble component of 
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clearance of this material from sites of cell death. It is important to note that, 
with low concentrations of CRP, nucleases in plasma did not appreciably solubilize 
the chromatin. Second, the present results suggest that chromatin which is not 
rapidly cleared (due to a  defect or depression in the CRP-complement mecha- 
nism) may act in some individuals as an immunogen, possibly resulting in  the 
production of antichromatin antibodies,  as seen  in  SLE plasma.  It  should be 
noted that many SLE patients have very depressed levels of complement, espe- 
cially when their disease is active (14); therefore, even if the CRP levels in an 
SLE patient were normal, the depressed complement levels could account for 
impaired chromatin  solubilization.  Even  if chromatin  were not  critical as an 
immunogen, an impaired CRP-complement solubilization mechanism might pro- 
vide antigen for either antigen-antibody complexes or the binding of antigen to 
basement membranes. 
Our present work closely relates to work from other laboratories.  In  1977, 
Gitlin  et al.  (16)  showed that  CRP  localized to  the nuclei of cells in  synovial 
biopsy samples from rheumatoid arthritis patients. Later (4),  it was shown that 
chromatin bound CRP very strongly, implying that the unknown ligand for CRP, 
previously thought to be in nuclei of synovial tissue, was chromatin. In  1981, 
Volanakis (13)  demonstrated that  pneumococcal C-polysaccharide-CRP com- 
plexes were solubilized by complement. The present paper links these previous 
results by demonstrating that complement solubilizes CRP-chromatin complexes. 
The mechanism by which CRP  mediates the solubilization of chromatin by 
complement is probably quite complex, as suggested by the time course study 
presented in Fig. 4. It appears that, frst, CRP binds to the chromatin (4).  Next, 
CRP either directly turns on the complement pathways or undergoes a confor- 
mation change in molecular structure due to binding to chromatin; this is then 
followed by complement activation. 
The experiments in which C lq-deficient serum did not suppport chromatin 
solubilization via CRP, even after C 1  q was added back (see Results), suggest that 
there are some additional factor(s) in serum which can bind to CRP immobilized 
to  chromatin and  that  the resulting  complex may activate complement. The 
same results were reported by Volanakis (13) for pneumococcal C-polysaccha- 
ride-CRP complexes. He found that serum which had been passed through Bio- 
Rex-70 (hence, C 1  q-deficient) did not support solubilization when C 1  q was added 
back (13). 
Similarly, de Beer et al. (27) reported that aggregated CRP bound, strongly 
and specifically, low density lipoprotein and very low density lipoprotein. There- 
fore, whether complement activation by CRP-chromatin complexes requires low 
density lipoproteins should be investigated. We are currently investigating the 
possibility that low density lipoproteins were removed from serum by Bio-Rex- 
70. 
As far as the nature of the complement is concerned, the experiments with 
genetically Cu-deficient serum showed that the alternative complement pathway 
plays a  minor role in the chromatin solubilization process but that the classical 
pathway seems to be the major route. Again, this parallels the results reported 
by Volanakis on the complement requirements for the solubilization of pneu- 
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Treatment  with proteinase K solubilizes chromatin  by digesting the histones 
bound to the  DNA,  thereby removing them,  leaving the  DNA highly charged 
and,  thus,  soluble.  A  similar  mechanism  may be  initiated  by CRP-chromatin 
complexes  in  which  the  complement  enzymes digest  histones  or  strip  certain 
histones from the DNA. 
As noted above, rabbit anti-human  H2B precipitated 43% of the solubilized 
product, indicating that some of the core histones are probably still bound to the 
solubilized DNA.  Further  characterization  of the solubilized product was com- 
plicated by the slow degradation of the solubilized DNA in serum, and possibly 
by the solubilized product binding Clq (28) or other serum factors to activate 
complement (20). However, in the absence of CRP (Fig.  1), insoluble chromatin 
did not appreciably consume the hemolytic activity of serum in the duration of 
our experiments. 
We have shown that  chromatin-bound  rabbit  CRP diminishes  the  hemolytic 
activity of rabbit serum. This is the first time that CRP from a nonhuman species 
has been shown to interact with the complement system from the same species. 
Because it has been believed that  bound CRP did not deplete complement in 
other species, the precise involvement of CRP with complement has been unclear. 
Further experiments using chromatin and CRP from other species may illuminate 
the interaction of CRP with complement throughout all of nature. 
Our current  hypothesis about the binding site for CRP on chromatin  is that 
CRP binds to the nucleosome core where exposed amino groups on histones are 
adjacent to phosphate  moieties of DNA.  The  stereochemical  arrangements  of 
these functionalities would mimic the phosphate-quaternary amine configuration 
seen in  PC,  the  putative  ligand  for CRP.  However, the  histone-DNA  binding 
region(s) appears to be favored over PC because the affinity of nucleosome core 
particles for the PC-binding site on CRP exceeds the affinity of PC for CRP by 
several  orders  of magnitude  (4).  We also believe that  histones  and  DNA are 
required for CRP to bind to chromatin, because it was previously demonstrated 
(30) that CRP does not bind to histones or DNA alone in a PC-inhibitable, Ca  2+- 
dependent manner, as is the situation with CRP bound to chromatin (4). 
It has been known for several years that phosphate with heparin, a polyanion, 
will solubilize chromatin by disrupting the nucleosome core structure (31). This 
supports our argument  that disruption of the nucleosome by CRP and comple- 
ment  may be the  mechanism  by which  chromatin  is solubilized,  although  the 
mechanism of disruption may not be the same. 
The finding of antibodies reactive with CRP in a sample of SLE plasma should 
not  come as a  complete surprise,  as antibodies  to  several  plasma  components 
have been reported in SLE (15). There have been several unsuccessful attempts 
to  link  CRP  to  SLE  (17-20).  Nonsensitive  detection  methods  were used  that 
could detect only elevated levels of CRP.  In each study,  CRP was elevated in 
some but not all cases. The authors failed to address whether non-elevated CRP 
levels were "normal" or abnormally low. The lowest value ever reported (2) for 
CRP in normal individuals is 68 ng/ml, found in one of a group of 153 healthy 
blood donors whose range  was 68-8,200  ng/ml  and  whose median  and mean 
were 580 and  109 ng/ml, respectively. Two of the SLE patients in our group of 1354  C-REACTIVE  PROTEIN MEDIATES CHROMATIN SOLUBILIZATION 
eight had  36  and  21  ng/ml CRP,  respectively (Table  I), both  lower than the 
previously reported low for normals. 
By activating complement at a site of exposed cellular chromatin, CRP could 
be an important inducer of inflammation since certain peptides from the com- 
plement system are potent chemoattractants and activators of phagocytic leuko- 
cytes (21).  Thus, binding of CRP to chromatin at the site of inflammation may 
act  as  a  major  signal  for  the  immune response  to  repair  and  protect  tissue 
damage. 
Although CRP was discovered over fifty years ago, and has been associated 
with the great majority of diseases in which there is active inflammation or tissue 
destruction (22-25), its function has not been proposed. On the basis of the data 
presented here and previously (4), we suggest that one function of CRP, common 
to inflammatory lesions, is mediation of the removal ofchromatin and chromatin 
fragments from sites of inflammation or sites where ceil death has occurred, so 
as to allow the initiation of tissue repair. 
Summary 
We have studied the interaction of C-reactive protein (CRP)-chromatin com- 
plexes with serum.  The amount of chromatin solubilized by serum is directly 
proportional to the amount of CRP present. Serum minus C3 did not appreciably 
solubilize chromatin within the time allowed in these experiments regardless of 
the amount of CRP present. This indicates that, in addition to CRP, complement 
is  critical  to  the  solubilization process.  Studies  using  genetically C2-deficient 
serum and purified C2 indicate that the classical complement pathway is primarily 
involved in the solubilization, however, there may be minor involvement by the 
alternative pathway. We used an enzyme-linked immunosorbent assay to deter- 
mine the amounts of CRP  in  plasma from eight patients with systemic lupus 
erythematosus; two of the eight had  levels  of CRP  far  lower than previously 
reported for normal individuals, and an additional sample had antibodies reactive 
with CRP. Together, these results suggest that one of the functions of CRP is to 
mediate the removal of exposed nuclear DNA by complement-dependent solu- 
bilization  of chromatin.  A  defect  in  this  mechanism  could  (a)  facilitate the 
production of antibodies against chromatin components exposed due to tissue 
damage or (b) contribute to immune complexes containing the chromatin com- 
ponents released from damaged tissue because they are not rapidly cleared. 
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